Navigation Links
ThermoGenesis Reports Fourth Quarter and Year End 2011 Results; Annual Net Loss Reduced by More Than 50 Percent

RANCHO CORDOVA, Calif., Sept. 12, 2011 /PRNewswire/ -- ThermoGenesis Corp. (NASDAQ: KOOL), a leading supplier of innovative products and services that process and store adult stem cells in the practice of regenerative medicine, reported results for the fourth quarter and all of fiscal 2011.

For the quarter ended June 30, 2011, the Company reported revenues of $5.4 million, compared to $7.2 million in the fourth quarter a year ago and $5.2 million in the prior quarter. Disposable sales in the fourth quarter of fiscal 2011 were $3.0 million, compared with $4.8 million in the same period a year ago and $3.0 million in the prior quarter. ThermoGenesis reported a net loss of $1.2 million, or $0.07 per share, in the fourth quarter of 2011, versus a net loss of $171,000, or $0.01 per share, in the same period a year ago.

For fiscal 2011, ThermoGenesis reported sales of $23.4 million compared with revenues of $23.1 million in fiscal 2010. Disposable sales in fiscal 2011 were $13.8 million, compared with $14.3 million for fiscal 2010. The Company reported a net loss of $2.6 million, or $0.17 per share, compared with a net loss of $5.2 million, or $0.37 per share, in fiscal 2010. The Company ended fiscal 2011 with $12.3 million in cash and cash equivalents versus $13.5 million at the end of the third quarter of 2011 and $10.7 million at the end of fiscal 2010. Backlog at the end of fiscal 2011 was $1.1 million.

"We are pleased to report a $2.6 million reduction in our annual net loss, or an improvement of 51 percent versus 2010. We accomplished this despite nominal growth in revenues year-over-year.  We realized measurable improvements in gross margins due to operating efficiencies and lower supplier costs, and a more than $1 million decline in operating expenses. Our performance for the quarter reflected the continued softness in the U.S. and European cord blood markets. This was partially offset by an increase in Res-Q® (Res-Q) System disposable revenues," said J. Melville Engle, Chairman and Chief Executive Officer of ThermoGenesis.  

"During the quarter, we achieved two important milestones in our program to increase the market presence for our Res-Q technology. These included FDA clearance of our 510(k) submission for the preparation of autologous platelet rich plasma (PRP), and the commercial launch of Res-Q for bone marrow indications in India. Also during the quarter, we made an initial shipment of AXP® AutoXpress™ Platform (AXP) and disposables to our Latin American distributor, which are being placed with customers in Mexico and Brazil," he stated.

"Despite a challenging market environment, fiscal 2011 was marked by a number of major accomplishments, particularly our increased presence in China where we have a number of distributor and customer relationships with leading regenerative medicine companies. We also initiated several clinical evaluations for our products, including studies involving Res-Q in China and India.  With respect to our financial performance, we realized continued improvement in gross margins and operating expense levels, and strengthened our balance sheet by raising approximately $4 million of growth capital through an offering of stock and warrants," Engle noted.

"We are looking forward to achieving other key milestones in our long-term growth strategy during fiscal 2012. There is growing interest in our cord blood and bone marrow technologies, particularly in important international markets where we have strong partnerships with market leaders. Our plan is to leverage these strong technology assets for adoption in a wider range of indications, through the development of new products and strategic partnerships and joint ventures. At the same time, we will continue to position the company for profitability, while maintaining a strong balance sheet to support our initiatives," he added.

The Company said that it expects revenues for the first two quarters of fiscal 2012 will be relatively consistent with those of the fourth quarter 2011.

Company's Conference Call and WebcastManagement will hold a conference call today at 2 p.m., Pacific (5 p.m., Eastern) to review the fiscal 2011 fourth quarter results.

Conference call details:Dial-in (U.S.):1-800-860-2442Dial-in (Internationally):1-412-858-4600Conference Name:"ThermoGenesis"To listen to the audio webcast of the call during or after the event, please visit

An audio replay of the conference call will be available beginning approximately two hours after completion of the call for the following five business days.

To access the replay:Access number (U.S.):1-877-344-7529Access number (Internationally)1-412-317-0088Conference ID#:385107About ThermoGenesis Corp.ThermoGenesis Corp. ( is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products. These include:

  • The BioArchive® System, an automated cryogenic device, used by cord blood stem cell banks in more than 30 countries for cryopreserving and archiving cord blood stem cell units for transplant.
  • AXP® AutoXpress™ Platform (AXP), a proprietary family of automated devices that includes the AXP and the MXP™ MarrowXpress™ and companion sterile blood processing disposables for harvesting stem cells in closed systems. The AXP device is used for the processing of cord blood. The MXP is used for the preparation of cell concentrates, including stem cells, from bone marrow aspirates in the laboratory setting.
  • The Res-Q® 60 BMC (Res-Q), a point-of-care system designed for the preparation of cell concentrates, including stem cells, from bone marrow aspirates.
  • The CryoSeal® FS System, an automated device and companion sterile blood processing disposable, used to prepare fibrin sealants from plasma in about an hour. The CryoSeal FS System is approved in the U.S. for liver resection surgeries. The CryoSeal FS System has received the CE-Mark which allows sales of the product throughout the European community.

  • This press release contains forward-looking statements.  These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors including timing of FDA and foreign regulatory approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal years 2011 and 2012, and introduction of competitive products and other factors beyond our control could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2011 and 2012.  A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.

    ThermoGenesis Corp.
    Web site:
    Contact: Investor Relations
    +1-916-858-5107, or

    THERMOGENESIS CORP.Condensed Consolidated Balance Sheets

    (Unaudited)June 30,

    2011June 30,

    2010ASSETSCurrent assets: Cash and cash equivalents$12,309,000$10,731,000 Accounts receivable, net3,963,0006,095,000 Inventories6,348,0005,034,000 Other current assets420,000301,000Total current assets23,040,00022,161,000 Equipment, net1,310,0001,701,000 Other assets49,000168,000$24,399,000$24,030,000LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities: Accounts payable$1,791,000$2,383,000 Other current liabilities2,273,0003,191,000Total current liabilities4,064,0005,574,000Long-term liabilities242,000677,000Stockholders' equity20,093,00017,779,000$24,399,000$24,030,000THERMOGENESIS CORP.Condensed Consolidated Statements of Operations

    (Unaudited)Three Months Ended

    June 30,Year Ended

    June 30,2011201020112010Net revenues

    $5,378,000$7,176,000$23,400,000$23,088,000Cost of revenues

    3,512,0004,700,00014,563,00015,643,000Gross profit

    1,866,0002,476,0008,837,0007,445,000Expenses: Selling, general and administrative

    2,245,0001,711,0008,669,0007,686,000 Research and development

    789,000939,0003,003,0005,013,000Total operating expenses

    3,034,0002,650,00011,672,00012,699,000Interest and other income, net

    --3,000268,00061,000Net loss

    ($1,168,000)($171,000)($2,567,000)($5,193,000)Basic and diluted net loss per common

    ($0.07)($0.01)($0.17)($0.37)Shares used in computing per share data

    16,346,36614,023,24014,816,16314,023,240THERMOGENESIS CORP.Condensed Consolidated Statements of Cash Flows

    (Unaudited)Year Ended

    June 30,20112010Cash flows from operating activities: Net loss

    ($2,567,000)($5,193,000) Adjustments to reconcile net loss to net cash used
     in operating activities:Depreciation and amortization

    466,000492,000Stock based compensation expense

    960,000518,000   Loss on sale/retirement of equipment

    13,000-- Loss on impairment of equipment

    65,00026,000Accretion of discount on short-term investments

    --(2,000)Net change in operating assets and liabilities:Accounts receivable, net


    (1,338,000)34,000Other current assets

    1,000361,000Other assets

    119,00079,000Accounts payable

    (592,000)602,000Accrued payroll and related expenses

    75,000(572,000)Deferred revenue

    (604,000)(132,000)Other liabilities

    (822,000)1,156,000Net cash used in operating activities

    (2,092,000)(4,428,000)Cash flows from investing activities: Capital expenditures

    (266,000)(470,000)   Proceeds from sale of equipment

    17,000(6,741,000) Maturities of investments

    --15,719,000Net cash (used in)/provided by investing activities:

    (249,000)8,508,000Cash flows from financing activities:   Exercise of stock options

    7,000--   Issuance of common stock

    3,914,000-- Payments on capital lease obligations

    (2,000)(4,000)Net cash provided by/(used in) financing activities

    3,919,000(4,000)Net increase/(decrease) in cash and cash equivalents

    1,578,0004,076,000Cash and cash equivalents at beginning of period

    10,731,0006,655,000Cash and cash equivalents at end of period


    SOURCE ThermoGenesis Corp.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. ThermoGenesis Announces MXP Involvement in New Regenerative Medicine Initiatives
    2. ThermoGenesis Announces National Institute of Health Grant
    3. ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program
    4. ThermoGenesis Names Jorge Artiles Vice President, Chief Quality and Regulatory Affairs Officer
    5. ThermoGenesis Announces Reverse Stock Split Effective on NASDAQ Capital Market August 27, 2010
    6. ThermoGenesis Regains Compliance With NASDAQ Listing Rules
    7. ThermoGenesis Announces Fourth Quarter Revenues of $7.2 Million; Reduces Net Loss to $171,000
    8. ThermoGenesis Announces Platelet Rich Plasma (PRP) Res-Q Cardiovascular Licensing Agreement
    9. ThermoGenesis Corp. to Announce First Quarter Fiscal 2011 Results on November 4, 2010
    10. ThermoGenesis Reports 35 Percent Increase in First Quarter 2011 Revenues, Adds Strategic Advisor and Inks China Distribution Deal With Nanshan Memorial Medical Institute
    11. ThermoGenesis Signs Major Bone Marrow Product Distribution Agreement in China
    Post Your Comments:
    (Date:3/29/2017)... , USA, March 29, 2017 Stryker announced ... Cares by People magazine, in partnership with Great Place ... companies on the list. This list highlights the top ... succeeded in business while also demonstrating respect, compassion and ... To determine the companies on the ...
    (Date:3/29/2017)... 29, 2017 On March 28, the U.S. Food and ... with relapsing forms of multiple sclerosis (MS) and primary ... approved by the FDA for PPMS. Ocrevus is an ... "Multiple sclerosis can have a profound impact ... M.D., director of the Division of Neurology Products in ...
    (Date:3/29/2017)... March 29, 2017 News Commentary  ... Data published in a research report by ... reach a value of USD 55.8 billion by 2025. The projection takes ... States and a more open approach towards cannabis products around ... Florida , North Dakota , ...
    Breaking Medicine Technology:
    (Date:3/29/2017)... Yorba Linda, Ca (PRWEB) , ... March 29, ... ... a standard process in many scientific laboratories. The assembly protocols involve many repetitive ... is well suited for automation, which enables the high-throughput needed, and results in ...
    (Date:3/29/2017)... ... March 29, 2017 , ... The Wharton School of the University of Pennsylvania ... have made a $10 million gift to establish the Ken Moelis and Julie ... pathway to a Wharton MBA for highly-qualified Penn undergraduates whose academic and career interests ...
    (Date:3/28/2017)... ... March 28, 2017 , ... For many women, getting birth control isn’t as easy as ... they either don’t have access to a health care facility or a pharmacy within 60 ... of the United States or for many who are faced with health or personal issues ...
    (Date:3/28/2017)... ... ... The Thyroid Secret is a specialized 9-part documentary series ... recently launched on March 1, and Dr. Wentz discussed varied benefits and aspects ... Wentz is a licensed pharmacist and a foremost thyroid specialist. After being diagnosed ...
    (Date:3/28/2017)... ... March 28, 2017 , ... Via Oncology, the leading provider ... a free, public-facing tool for analyzing the costs of various drug regimens in ... information to patients, providers, insurers and pharmaceutical companies about the estimated costs of ...
    Breaking Medicine News(10 mins):